CST3 and chronic kidney disease: The use of cystatin C to confirm a diagnosis of chronic kidney disease resulted in reclassification of a small proportion (7.7%) of people as not having chronic kidney disease, but a much greater proportion were reclassified as having more advanced disease (59%).